Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soft cannabinoid analogues as potential anti-glaucoma agents.

A Buchwald1, C E Browne, W M Wu

  • 1Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, USA.

Die Pharmazie
|April 11, 2000
PubMed
Summary

Researchers developed a novel topical glaucoma medication based on cannabinoids. This "soft drug" aims for local eye pressure reduction without systemic side effects, offering a safer treatment for glaucoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Multifrequency attenuation patterns in age-related hearing loss: a longitudinal analysis using spline mixed-effects models].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026
Same author

[Perioperative digital surveillance with a multiparameter vital signs monitoring system in a gastric cancer patient with diabetes].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025
Same author

[Relationship between <i>GST</i> gene polymorphism and susceptibility to occupational noise induced hearing loss].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2025
Same author

[Analysis of factors associated with false-positive results and optimal positivity thresholds of quantitative fecal immunochemical test in colorectal cancer screening].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[Perioperative management of a patient with hemophilia a and high-titer inhibitors and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2025
Same author

[Exploration of the application of artificial intelligence assisted bleeding point recognition in laparoscopic pancreatic surgery].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2025

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Cannabinoids demonstrate intraocular pressure (IOP) lowering capabilities, suggesting therapeutic potential for glaucoma treatment.
  • Current cannabinoid therapies for glaucoma may cause undesirable central nervous system (CNS) and cardiovascular side effects.
  • There is a need for safer glaucoma agents with localized ocular effects and minimal systemic absorption.

Purpose of the Study:

  • To develop a novel, topically applied soft analogue of a cannabinoid-based anti-glaucoma agent.
  • To create a drug candidate that reduces IOP locally within the eye while avoiding systemic side effects.
  • To identify a lead compound with optimized properties for glaucoma treatment.

Main Methods:

  • A library of nitrogen-containing cannabinoid soft drug analogues was synthesized.

Related Experiment Videos

  • Compounds were ranked based on calculated physicochemical properties compared to a lead compound.
  • The lead compound underwent synthesis and preliminary pharmacological evaluation.

    • Main Results:

    • The synthesized lead compound demonstrated intraocular pressure lowering activity.
    • Structure-activity relationship analysis provided insights into drug design.
    • Pharmacological studies indicated the potential for localized ocular effect.

    Conclusions:

    • The developed soft cannabinoid analogue shows promise as a safer anti-glaucoma agent.
    • Topical application may allow for local IOP reduction without systemic adverse effects.
    • Further development could lead to a new class of glaucoma therapeutics with improved safety profiles.